PHILIPS INTERNATIONAL B.V.

Their core work

Philips International B.V. is the international holding entity of Royal Philips, the Dutch technology company headquartered in Eindhoven that specializes in health technology and medical devices. In H2020, this entity participated in projects focused on elderly healthcare and technology transfer best practices — roles consistent with Philips contributing industrial credibility, commercialization pathways, and real-world deployment experience to research consortia. As a non-SME private company from the Brainport Eindhoven high-tech ecosystem, they bring large-scale industrial validation capacity rather than fundamental research. Their engagement in technology transfer programs suggests an active interest in bridging public research and market deployment across Europe.

What they specialise in

How they've shifted over time

Their earliest H2020 engagement (PROGRESS-TT, 2015) was oriented around the innovation system itself — how public research organizations commercialize, cluster, and build capacity — suggesting a role as an industry exemplar advising on research-to-market pipelines. The subsequent project (REACH2020, 2016) shifted toward applied health technology for elderly populations, which is closer to Philips' core product and services business. With only two projects and a participation window ending in 2016, the trajectory is too short to identify a firm trend, but the shift from meta-innovation topics toward direct healthcare application is consistent with a company grounding its EU research activity closer to its commercial focus.

Limited data, but participation shifted from advising on innovation system practices toward direct involvement in patient-centered health technology deployment — a direction consistent with Philips' broader strategic pivot to health technology.

How they like to work

Philips International B.V. participated exclusively as a consortium partner in both H2020 projects, never taking on coordinator responsibilities, which suggests they engage as an industrial validation and commercialization resource rather than driving research agendas. Despite only two projects, they accumulated 24 unique consortium partners across 10 countries, indicating participation in large, well-networked consortia. This profile is typical of large corporations that join EU projects to contribute deployment expertise and industry grounding, not to lead fundamental research.

24 unique consortium partners across 10 countries from just two projects signals participation in substantial multi-stakeholder consortia. Their geographic footprint is European, with the Netherlands as the base but partnerships spanning at least 10 countries.

What sets them apart

As part of the Royal Philips group — one of Europe's most recognized health technology companies — this entity carries significant industrial credibility and the ability to connect research outputs to real-world product and service pipelines at scale. Their involvement in technology transfer programs positions them as an industry benchmark for how large companies absorb and commercialize research. However, their H2020 footprint through this specific legal entity is very narrow (2 projects, €133K EC funding), suggesting the bulk of Philips' EU research activity likely runs through other group entities not captured here.

Highlights from their portfolio

• REACH2020
  A long-running project (2016–2020) directly in Philips' core health technology domain, addressing elderly activity and customized healthcare — the most strategically relevant project for understanding Philips' applied research contribution.
• PROGRESS-TT
  The only project with recorded EC funding (€133K), focused on technology transfer best practices across public research organizations — notable for revealing Philips' role as an industrial knowledge-transfer advisor to the European research community.